Phase 2 N=29 Phase 2 Trial of a Nicotinic Agonist in Schizophrenia
Schizophrenia
Primary: Neurocognitive Performance — 4.5; 6.1; 7.6 t-score change from baseline
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=232 Clinical Trial of Topically-applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction (ED)
Erectile Dysfunction
Primary: Erectile Function (EF) Domain Score of the International Index of Erectile Function (IIEF) — 18.5; 19.6 score on a scale — p=0.0132
Phase 2 N=449 Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
Chronic Myeloid Leukemia · Ph+ Acute Lymphoblastic Leukemia
Primary: Percentage of CP-CML Participants With Major Cytogenetic Response (MCyR) — 50.7; 70.3 percentage of participants
Phase 2 N=30 Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4
Acute Hepatitis C · HIV
Primary: Sustained Virological Response 12 Weeks Post-treatment (SVR12) — 28 Participants
Phase 2 N=6 Ranolazine Mediated PVC Reduction in Ischemic Heart Disease
Ventricular Premature Complexes · Myocardial Ischemia
Primary: The Effect of Ranolazine on the PVC Burden Over 30 Days — 5.71; 5.495 percentage of PVC burden
Phase 2 N=84 Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis
Tuberculosis · HIV Infections
Primary: Mean Change From Baseline in QTcF — 12.3; 8.6; 20.7 milliseconds (ms)
Phase 2 N=75 A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Non-Alcoholic Steatohepatitis
Primary: Mean Change in Percent Hepatic Fat Fraction (%) by Magnetic Resonance Imaging (MRI) From Baseline to Week 16 — -8.43; -6.45; -1.26; -6.77 percentage — p=0.0004
Phase 2 N=70 A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8
Hyperkalemia
Primary: Mean Absolute Change in S-K From Baseline Until 4h After Start of Dosing With SZC/Placebo — -0.41; -0.27 mmol/L
Phase 2 N=66 Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)
MPN (Myeloproliferative Neoplasms)
Primary: Percent Change From Baseline in Spleen Volume at Week 24 by Final Titrated Dose — -11.6; -17.4; -22.4; -13.4 Percentage change from baseline — p=0.0250
Phase 2 N=9 αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface · Malignant Peritoneal Mesothelioma · Peritoneal Carcinomatosis
Primary: Recommended Phase 2 Dose (RP2D) (Phase 1) — 5; 0; 4 Participants
Phase 2 N=80 Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Primary: ALS Functional Rating Scale-Revised (ALSFRS-R) — -1.00; -1.26 score on a scale
Phase 2 N=57 Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis
Hepatitis, Alcoholic
Primary: Gastrointestinal Safety Endpoints — 15; 27; 7; 14 Incidents
Phase 2 N=44 Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes
Hepatic Steatosis
Primary: Absolute Change in Liver Fat Percentage (Randomized Population) — -0.04; -5.37 liver fat percentage — p=0.003
Phase 2 N=61 Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
Advanced Cancers · Lymphoma
Primary: Frequency of DLT — 16; 28; 40 Dose-limiting toxicities
Phase 2 N=36 Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Primary: Number of Participants With Adverse Events — 5; 8; 8; 1 Participants